Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 6;10(10):CD008209.
doi: 10.1002/14651858.CD008209.pub2.

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency

Laurentiu Craciunas  1 , Nikolaos Zdoukopoulos  2 , Suganthi Vinayagam  3 , Lamiya Mohiyiddeen  4
Affiliations

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency

Laurentiu Craciunas et al. Cochrane Database Syst Rev. .

Abstract

Background: Premature ovarian insufficiency (POI) is a clinical syndrome resulting from loss of ovarian function before the age of 40. It is a state of hypergonadotropic hypogonadism, characterised by amenorrhoea or oligomenorrhoea, with low ovarian sex hormones (oestrogen deficiency) and elevated pituitary gonadotrophins. POI with primary amenorrhoea may occur as a result of chromosomal and genetic abnormalities, such as Turner syndrome, Fragile X, or autosomal gene defects; secondary amenorrhoea may be iatrogenic after the surgical removal of the ovaries, radiotherapy, or chemotherapy. Other causes include autoimmune diseases, viral infections, and environmental factors; in most cases, POI is idiopathic. Appropriate replacement of sex hormones in women with POI may facilitate the achievement of near normal uterine development. However, the optimal effective hormone therapy (HT) regimen to maximise the reproductive potential for women with POI remains unclear.

Objectives: To investigate the effectiveness and safety of different hormonal regimens on uterine and endometrial development in women with POI.

Search methods: We searched the Cochrane Gynaecology and Fertility (CGF) Group trials register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, and two trials registers in September 2021. We also checked references of included studies, and contacted study authors to identify additional studies.

Selection criteria: We included randomised controlled trials (RCTs) investigating the effect of various hormonal preparations on the uterine development of women diagnosed with POI.

Data collection and analysis: We used standard methodological procedures recommended by Cochrane. The primary review outcome was uterine volume; secondary outcomes were endometrial thickness, endometrial histology, uterine perfusion, reproductive outcomes, and any reported adverse events.

Main results: We included three studies (52 participants analysed in total) investigating the role of various hormonal preparations in three different contexts, which deemed meta-analysis unfeasible. We found very low-certainty evidence; the main limitation was very serious imprecision due to small sample size. Conjugated oral oestrogens versus transdermal 17ß-oestradiol We are uncertain of the effect of conjugated oral oestrogens compared to transdermal 17ß-oestradiol (mean difference (MD) -18.2 (mL), 95% confidence interval (CI) -23.18 to -13.22; 1 RCT, N = 12; very low-certainty evidence) on uterine volume, measured after 12 months of treatment. The study reported no other relevant outcomes (including adverse events). Low versus high 17ß-oestradiol dose We are uncertain of the effect of a lower dose of 17ß-oestradiol compared to a higher dose of 17ß-oestradiol on uterine volume after three or five years of treatment, or adverse events (1 RCT, N = 20; very low-certainty evidence). The study reported no other relevant outcomes. Oral versus vaginal administration of oestradiol and dydrogesterone We are uncertain of the effect of an oral or vaginal administration route on uterine volume and endometrial thickness after 14 or 21 days of administration (1 RCT, N = 20; very low-certainty evidence). The study reported no other relevant outcomes (including adverse events).

Authors' conclusions: No clear conclusions can be drawn in this systematic review, due to the very low-certainty of the evidence. There is a need for pragmatic, well designed, randomised controlled trials, with adequate power to detect differences between various HT regimens on uterine growth, endometrial development, and pregnancy outcomes following the transfer of donated gametes or embryos in women diagnosed with POI.

PubMed Disclaimer

Conflict of interest statement

LC, NZ, SV, and LM have no interests to declare.

Figures

1
1
Study PRISMA flow diagram
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study
4
4
Forest plot of comparison: 1 Conjucted oral oestrogens versus transdermal 17ß‐estradiol, outcome: 1.1 Uterine volume (mL)
1.1
1.1. Analysis
Comparison 1: Conjugated oral oestrogens versus transdermal 17ß‐estradiol, Outcome 1: Uterine volume (mL)
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD008209

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Cleemann 2020 {published data only}
    1. Cleemann L, Holm K, Fallentin E, Møller N, Kristensen B, Skouby SO, et al. Effect of dosage of 17ß-Estradiol on uterine growth in Turner syndrome—a randomized controlled clinical pilot trial. The Journal of Clinical Endocrinology & Metabolism 2020;105(3):e716-24. [DOI: 10.1210/clinem/dgz061] [PMID: ] - DOI - PubMed
Feng 2021 {published data only}
    1. Feng W, Nie L, Wang X, Yang F, Pan P, Deng X. Effect of oral versus vaginal administration of estradiol and dydrogesterone on the proliferative and secretory transformation of endometrium in patients with premature ovarian failure and preparing for assisted reproductive technology. Drug Design, Development and Therapy 2021;15:1521-9. [DOI: 10.2147/DDDT.S297236] [PMID: ] - DOI - PMC - PubMed
Nabhan 2009 {published data only}
    1. Nabhan ZM, Dimeglio LA, Qi R, Perkins SM, Eugster EA. Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. Journal of Clinical Endocrinology and Metabolism 2009;94:2009-14. [DOI: 10.1210/jc.2008-2123] [PMID: ] - DOI - PubMed

References to studies excluded from this review

Achiron 1995 {published data only}
    1. Achiron R, Levran D, Sivan E, Lipitz S, Dor J, Mashiach S. Endometrial blood flow response to hormone replacement therapy in women with premature ovarian failure: a transvaginal Doppler study. Fertility and Sterility 1995;63:550-4. [DOI: 10.1016/s0015-0282(16)57424-x] [PMID: ] - DOI - PubMed
Badawy 2007 {published data only}
    1. Badawy A, Goda H, Ragab A. Induction of ovulation in idiopathic premature ovarian failure: a randomized double-blind trial. Reproductive Biomedicine Online 2007;15:215-9. [DOI: 10.1016/s1472-6483(10)60711-0] [PMID: ] - DOI - PubMed
Benetti‐Pinto 2020 {published data only}
    1. Benetti-Pinto CL, Giraldo HP, Giraldo AE, Mira TA, Yela DA. Interferential current: a new option for the treatment of sexual complaints in women with premature ovarian insufficiency using systemic hormone therapy: a randomized clinical trial. Menopause 2020;27:519-25. [DOI: 10.1097/GME.0000000000001501] [PMID: ] - DOI - PubMed
Ben‐Naghi 2014 {published data only}
    1. Ben-Nagi J, Panay N. Premature ovarian insufficiency: how to improve reproductive outcome? Climacteric 2014;17:242-6. [DOI: 10.3109/13697137.2013.860115] [PMID: ] - DOI - PubMed
Burgos 2017 {published data only}
    1. Burgos N, Cintron D, Latortue-Albino P, Serrano V, Rodriguez Gutierrez R, Faubion S, et al. Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review. Endocrine 2017;58:13-425. [DOI: 10.1007/s12020-017-1435-x] [PMID: ] - DOI - PMC - PubMed
Fraison 2019 {published data only}
    1. Fraison E, Crawford G, Casper G, Harris V, Ledger W. Pregnancy following diagnosis of premature ovarian insufficiency: a systematic review. Reproductive Biomedicine Online 2019;39:467-76. [DOI: 10.1016/j.rbmo.2019.04.019] [PMID: ] - DOI - PubMed
Gault 2011 {published data only}
    1. Gault EJ, Perry RJ, Cole TJ, Casey S, Paterson WF, Hindmarsh PC, et al, British Society for Paediatric Endocrinology and Diabetes. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial. BMJ 2011;342:d1980. [DOI: 10.1136/bmj.d1980] [PMID: ] - DOI - PMC - PubMed
Gelbaya 2011 {published data only}
    1. Gelbaya T, Vitthala S, Nardo L, Seif M. Optimizing hormone therapy for future reproductive performance in women with premature ovarian failure. Gynecological Endocrinology 2011;27:1-7. [DOI: 10.3109/09513590.2010.501875] [PMID: ] - DOI - PubMed
Kasteren 1999 {published data only}
    1. Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Human Reproduction Update 1999;5:483-92. [DOI: 10.1093/humupd/5.5.483] [PMID: ] - DOI - PubMed
Labarta 2012 {published data only}
    1. Labarta JI, Moreno ML, López-Siguero JP, Luzuriaga C, Rica I, Sánchez-del Pozo J, et al, Spanish Turner Working Group. Individualised vs fixed dose of oral 17β-oestradiol for induction of puberty in girls with Turner syndrome: an open-randomised parallel trial. European Journal of Endocrinology / European Federation of Endocrine Societies 2012;167:523-9. [DOI: 10.1530/EJE-12-0444] [PMID: ] - DOI - PubMed
Li 1992 {published data only}
    1. Li TC, Cooke ID, Warren MA, Goolamallee M, Graham RA, Aplin JD. Endometrial responses in artificial cycles: a prospective study comparing four different oestrogen dosages. British Journal of Obstetrics and Gynaecology 1992;99:751-6. [DOI: 10.1111/j.1471-0528.1992.tb13878.x] [PMID: ] - DOI - PubMed
Liu 2019 {published data only}
    1. Liu W, Nguyen TN, Tran Thi TV, Zhou S. Kuntai capsule plus hormone therapy vs. hormone therapy alone in patients with premature ovarian failure: a systematic review and meta-analysis. Evidence-based Complementary and Alternative Medicine : ECAM 2019;2019:2085804. [DOI: 10.1155/2019/2085804] - DOI - PMC - PubMed
O'Donnell 2012 {published data only}
    1. O'Donnell RL, Warner P, Lee RJ, Walker J, Bath LE, Kelnar CJ, et al. Physiological sex steroid replacement in premature ovarian failure: randomized crossover trial of effect on uterine volume, endometrial thickness and blood flow, compared with a standard regimen. Human Reproduction (Oxford, England) 2012;27:1130-8. [DOI: 10.1093/humrep/des004] [PMID: ] - DOI - PubMed
Robles 2013 {published data only}
    1. Robles A, Checa MA, Prat M, Carreras R. Medical alternatives to oocyte donation in women with premature ovarian failure: a systematic review. Gynecological Endocrinology 2013;29:632-7. [DOI: 10.3109/09513590.2013.797397] [PMID: ] - DOI - PubMed
Ross 2011 {published data only}
    1. Ross JL, Quigley CA, Cao D, Feuillan P, Kowal K, Chipman JJ, et al. Growth hormone plus childhood low-dose estrogen in Turner's syndrome. New England Journal of Medicine 2011;364:1230-42. [DOI: 10.1056/NEJMoa1005669] [PMID: ] - DOI - PMC - PubMed
Snajderova 2003 {published data only}
    1. Snajderova M, Mardesic T, Lebl J, Gerzova H, Teslik L, Zapletalova J, Czech National Study Group for HRT Optimization in Paediatric and Adolescent Endocrinology and Gynaecology. The uterine length in women with Turner syndrome reflects the postmenarcheal daily estrogen dose. Hormone Research 2003;60:198-204. [DOI: 10.1159/000073233] [PMID: ] - DOI - PubMed
Sullivan 2016 {published data only}
    1. Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertility and Sterility 2016;106:1588-99. [DOI: 10.1016/j.fertnstert.2016.09.046] [PMID: ] - DOI - PMC - PubMed
Tartagni 2007 {published data only}
    1. Tartagni M, Cicinelli E, De Pergola G, De Salvia MA, Lavopa C, Loverro G. Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. Fertility and Sterility 2007;87:858-61. [DOI: 10.1016/j.fertnstert.2006.08.086] [PMID: ] - DOI - PubMed
Webber 2017 {published data only}
    1. Webber L, Anderson RA, Davies M, Janse F, Vermeulen N. HRT for women with premature ovarian insufficiency: a comprehensive review. Human Reproduction Open 2017;2017(2):hox007. [DOI: 10.1093/hropen/hox007] [PMID: ] - DOI - PMC - PubMed

Additional references

Abdalla 1994
    1. Abdalla HI, Brooks AA, Johnson MR, Kirkland A, Thomas A, Studd JW. Endometrial thickness: a predictor of implantation in ovum recipients? Human Reproduction (Oxford, England) 1994;9:363-5. [PMID: ] - PubMed
ACOG 2022
    1. ACOG. Primary ovarian insufficiency in adolescents and young women. Committee opinion number 605. Available at www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2014/... (accessed 19 September 2022).
Andreyko 1988
    1. Andreyko JL, Blumenfeld Z, Marshall LA, Monroe SE, Hricak H, Jaffe RB. Use of an agonistic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging. American Journal of Obstetrics and Gynecology 1988;158:903-10. [PMID: ] - PubMed
Baron 1984
    1. Baron JA. Smoking and estrogen-related disease. American Journal of Epidemiology 1984;119:9-22. [PMID: ] - PubMed
Beral 2005
    1. Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365(9470):1543-51. [DOI: 10.1016/S0140-6736(05)66455-0] [PMID: ] - DOI - PubMed
Beral 2007
    1. Beral V, Bull D, Green J, Reeves G, Million Women Study Collaborators, . Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369(9574):1703-10. [DOI: 10.1016/S0140-6736(07)60534-0] [PMID: ] - DOI - PubMed
Bodri 2006
    1. Bodri D, Vernaeve V, Figueras F, Vidal R, Guillén JJ, Coll O. Oocyte donation in patients with Turner's syndrome: a successful technique but with an accompanying high risk of hypertensive disorders during pregnancy. Human Reproduction (Oxford, England) 2006;21:829-32. [PMID: ] - PubMed
Coulam 1986
    1. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstetrics and Gynecology 1986;67:604-6. [PMID: ] - PubMed
Craciunas 2019
    1. Craciunas L, Gallos I, Chu J, Bourne T, Quenby S, Brosens JJ, et al. Conventional and modern markers of endometrial receptivity: a systematic review and meta-analysis. Human Reproduction Update 2019;25:202-23. [PMID: ] - PubMed
Craciunas 2021
    1. Craciunas L, Pickering O, Chu J, Choudhary M, Žurauskienė J, Coomarasamy A. The transcriptomic profile of endometrial receptivity in recurrent miscarriage. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2021;261:211-16. [PMID: ] - PubMed
Critchley 2002
    1. Critchley HO, Bath LE, Wallace WH. Radiation damage to the uterus – review of the effects of treatment of childhood cancer. Human Fertility 2002;5(2):61-6. [DOI: 10.1080/1464727022000198942] [PMID: ] - DOI - PubMed
Demas 1986
    1. Demas BE, Hricak H, Jaffe RB. Uterine MR imaging: effects of hormonal stimulation. Radiology 1986;159:123-6. [PMID: ] - PubMed
Doerr 2005
    1. Doerr HG, Bettendorf M, Hauffa BP, Mehls O, Partsch CJ, Said E, et al. Uterine size in women with Turner syndrome after induction of puberty with estrogens and long-term growth hormone therapy: results of the German IGLU Follow-up Study 2001. Human Reproduction (Oxford, England) 2005;20:1418-21. [PMID: ] - PubMed
ESHRE 2016
    1. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction (Oxford, England) 2016;31(5):926-37. [DOI: 10.1093/humrep/dew027] [PMID: ] - DOI - PubMed
Foudila 1999
    1. Foudila T, Söderström-Anttila V, Hovatta O. Turner's syndrome and pregnancies after oocyte donation. Human Reproduction (Oxford, England) 1999;14:532-5. [PMID: ] - PubMed
Goswami 2007
    1. Goswami D, Conway GS. Premature ovarian failure. Hormone Research 2007;68:196-202. [PMID: ] - PubMed
GRADEpro GDT [Computer program]
    1. McMaster University and Evidence Prime, 2022 GRADEpro Guideline Development Tool . Version accessed 18.04.2022. McMaster University and Evidence Prime, 2022. Available from gradepro.org.
Grady 2002
    1. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al, HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57. [PMID: ] - PubMed
Gravholt 1996
    1. Gravholt CH, Juul S, Naeraa RW, Hansen J. Prenatal and postnatal prevalence of Turner's syndrome: a registry study. BMJ 1996;312:16-21. [PMID: ] - PMC - PubMed
Guttmann 2001
    1. Guttmann H, Weiner Z, Nikolski E, Ish-Shalom S, Itskovitz-Eldor J, Aviram M, et al. Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. Clinical Endocrinology 2001;54:159-64. [PMID: ] - PubMed
Hendrix 2006
    1. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al, WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425-34. [PMID: ] - PubMed
Higgins 2017
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook/archive/v5.2.
Higgins 2021
    1. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook/archive/v6.2.
Hovatta 1999
    1. Hovatta O. Pregnancies in women with Turner's syndrome. Annals of Medicine 1999;31(2):106-10. [PMID: ] - PubMed
Jacoby 2011
    1. Jacoby VL, Grady D, Wactawski-Wende J, Manson JE, Allison MA, Kuppermann M, et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Archives of Internal Medicine 2011;171:760-8. [PMID: ] - PubMed
Kelleher 2019
    1. Kelleher AM, DeMayo FJ, Spencer TE. Uterine glands: developmental biology and functional roles in pregnancy. Endocrine Reviews 2019;40:1424-45. [PMID: ] - PMC - PubMed
Kokcu 2010
    1. Kokcu A. Premature ovarian failure from current perspective. Gynecological Endocrinology 2010;26:555-62. [PMID: ] - PubMed
Krailo 1983
    1. Krailo MD, Pike MC. Estimation of the distribution of age at natural menopause from prevalence data. American Journal of Epidemiology 1983;117:356-61. [PMID: ] - PubMed
Kuh 2005
    1. Kuh D, Butterworth S, Kok H, Richards M, Hardy R, Wadsworth ME, et al. Childhood cognitive ability and age at menopause: evidence from two cohort studies. Menopause 2005;12:475-82. [PMID: ] - PubMed
La Marca 2006
    1. La Marca A, Pati M, Orvieto R, Stabile G, Carducci Artenisio A, Volpe A. Serum anti-müllerian hormone levels in women with secondary amenorrhea. Fertility and Sterility 2006;85:1547-9. [PMID: ] - PubMed
Larsen 2004
    1. Larsen EC, Schmiegelow K, Rechnitzer C, Loft A, Müller J, Andersen AN. Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. Acta Obstetricia et Gynecologica Scandinavica 2004;83:96-102. [PMID: ] - PubMed
Luborsky 2003
    1. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Human Reproduction (Oxford, England) 2003;18:199-206. [PMID: ] - PubMed
McCarthy 1986
    1. McCarthy S, Tauber C, Gore J. Female pelvic anatomy: MR assessment of variations during the menstrual cycle and with use of oral contraceptives. Radiology 1986;160:119-23. [PMID: ] - PubMed
McDonnell 2003
    1. McDonnell CM, Coleman L, Zacharin MR. A 3-year prospective study to assess uterine growth in girls with Turner's syndrome by pelvic ultrasound. Clinical Epidemiology 2003;58:446-50. [PMID: ] - PubMed
McKenzie 2022
    1. McKenzie JE, Brennan SE. Chapter 12: Synthesizing and presenting findings using other methods. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
Melner 1999
    1. Melner MH, Feltus FA. Autoimmune premature ovarian failure – endocrine aspects of a T cell disease. Endocrinology 1999;140(8):3401-3. [DOI: 10.1210/endo.140.8.7046] [PMID: ] - DOI - PubMed
Mertens 2001
    1. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr, Ruccione K, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. Journal of Clinical Oncology 2001;19:3163-72. [PMID: ] - PubMed
Meskhi 2006
    1. Meskhi A, Seif MW. Premature ovarian failure. Current Opinion in Obstetrics & Gynecology 2006;18:418-26. [PMID: ] - PubMed
MHRA 2007
    1. Regulating medicines and and medical devices (MHRA). Hormone replacement therapy. In: Drug Safety Update: Volume 1, Issue 2, September 2007. Available from webarchive.nationalarchives.gov.uk/ukgwa/20141206041936/http://www.mhra.....
Parker 2009
    1. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstetrics and Gynecology 2009;113:1027-37. [PMID: ] - PMC - PubMed
Peverill 2003
    1. Peverill RE. Hormone therapy and venous thromboembolism. Best Practice & Research. Clinical Endocrinology & Metabolism 2003;17:149-64. [PMID: ] - PubMed
Rocca 2006
    1. Rocca WA, Grossardt BR, Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncology 2006;7:821-8. [PMID: ] - PubMed
Rossouw 2007
    1. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77. [PMID: ] - PubMed
Scarabin 2003
    1. Scarabin PY, Oger E, Plu-Bureau G, EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32. [PMID: ] - PubMed
Shah 2005
    1. Shah NR, Borenstein J, Dubois RW. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 2005;12:668-78. [PMID: ] - PMC - PubMed
Shuster 2010
    1. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas 2010;65:161-6. [PMID: ] - PMC - PubMed
Sun 2012
    1. Sun L, Tan L, Yang F, Luo Y, Li X, Deng HW, et al. Meta-analysis suggests that smoking is associated with an increased risk of early natural menopause. Menopause 2012;19:126-32. [PMID: ] - PubMed
Torres‐Santiago 2013
    1. Torres-Santiago L, Mericq V, Taboada M, Unanue N, Klein KO, Singh R, et al. Metabolic effects of oral versus transdermal 17β-estradiol (E₂): a randomized clinical trial in girls with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2013;98:2716-24. [PMID: ] - PMC - PubMed
van Noord 1997
    1. Noord PA, Dubas JS, Dorland M, Boersma H, te Velde E. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertility and Sterility 1997;68:95-102. [PMID: ] - PubMed
Wallace 1989
    1. Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR. Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clinical Oncology (Royal College of Radiologists (Great Britain)) 1989;1:75-9. [PMID: ] - PubMed
Wassertheil‐Smoller 2003
    1. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al, WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84. [PMID: ] - PubMed
Whalley 2004
    1. Whalley LJ, Fox HC, Starr JM, Deary IJ. Age at natural menopause and cognition. Maturitas 2004;49:148-56. [PMID: ] - PubMed
Zhang 1995
    1. Zhang L, Rees MC, Bicknell R. The isolation and long-term culture of normal human endometrial epithelium and stroma. Expression of mRNAs for angiogenic polypeptides basally and on oestrogen and progesterone challenges. Journal of Cell Science 1995;108:323-31. [PMID: ] - PubMed

Publication types

LinkOut - more resources